Digital Therapeutic Based Investigation to Improve Glycemic Control in Patients With Type 2 Diabetes and Residual Hyperglycemia on Stable Medical Therapy (BRIGHT)

Digital Therapeutic Based Investigation to Improve Glycemic Control in Patients With Type 2 Diabetes and Residual Hyperglycemia on Stable Medical Therapy

Randomized, Controlled, Multicenter, Pragmatic, Trial With Open-label Extension of PHOENIX to Improve Glycemic Control in Adults With Type 2 Diabetes in a Real-world Setting

CPC Clinical Research, University of Colorado, Denver, Ascension Health, Department of Veterans Affairs Hospital Durham, NC, University of Colorado Health Clinics

Randomized, controlled, multicenter, pragmatic, pivotal trial with open-label extension evaluating the hypothesis that PHOENIX, an investigational digital therapeutic intended to help patients with type 2 diabetes improve their glycemic control, will lower hemoglobin A1c (HbA1c) compared to a control application added to usual care and across a broad range of patients in a real-world setting

This randomized, controlled, multicenter, parallel-arm, pragmatic pivotal trial with extension will evaluate the hypothesis that PHOENIX compared to a control application, both on top of usual care, will lower HbA1c in real world clinical practice. Approximately five-hundred (500) adults with type 2 diabetes will be randomized (1:1) to PHOENIX or the control application. Most clinical data will be collected via the electronic medical records (EMR) system with limited additional contacts to ascertain adverse device effects (ADEs), adverse events (AEs) and clinical events which may have occurred outside the health system and were not recorded in the EMR. For primary efficacy endpoint assessment, a requisition form for HbA1c at a local laboratory will be provided if HbA1c is not available from the EMR within the 90- and 180-day time windows. During the extension phase, biomarker endpoint data will only be collected from the EMR. For all participants, clinical and healthcare utilization data will be extracted from their EMR for the period from 180 days prior to enrollment to 720 days after enrollment.

Patients will be randomized to an intervention arm or control arm. After 6 months, patients in the control arm will be able to cross over to using the intervention.

While patients and providers will not be told which arm they are in, it will be obvious when they complete the installation of the mobile application which arm they are in.

Patients will have access to a control mobile application for 180 days and then will have the option to use the treatment for the remainder of the 720 day study

PHOENIX is a software application that delivers treatment to participants with type 2 diabetes, using behavioral therapy. PHOENIX is accessed via the participants' smartphone. The behavioral intervention process involves: Identifying maladaptive thoughts based on misinformed core beliefs that lead to disease-promoting behaviors; replacing maladaptive core beliefs with adaptive ways of thinking; and providing collaborative construction of behavioral exercises to test core beliefs. Each week, PHOENIX asks participants to complete a new lesson, along with one skill exercise. The lessons are expected to take between 10-20 minutes to complete. In addition to completing a lesson and skill, participants will be directed to report plant-based meals consumed and minutes of exercise completed and to measure their blood sugar daily.

The app asks patients brief questions about their health but does not include any behavioral therapy.

Occurrence, relatedness and severity of adverse device effects and adverse events between treatment groups

Occurrence, relatedness and severity of adverse device effects and adverse events between treatment groups

Inclusion Criteria: Age 18-75 years, inclusive at the time of signing the informed consent Type 2 diabetes on stable anti-diabetic regimen for at least three (3) months HbA1c 7.0% to 10.9% (within thirty [30] days of signing the informed consent form [ICF]) Able to use PHOENIX e.g., English fluent, smartphone is capable of running the study intervention. Exclusion Criteria: Current use of outpatient prandial insulin In the opinion of the investigator, life expectancy < one (1) year COVID-19 diagnosis within thirty (30) days prior to randomization.